Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cetrelimab + Niraparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cetrelimab||JNJ63723283|JNJ 63723283|JNJ-63723283||Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 112||Cetrelimab (JNJ-63723283) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 28943093).|
|Niraparib||Zejula||MK4827||PARP Inhibitor (Pan) 29||Zejula (niraparib) binds to and inhibits PARP, which may result in the accumulation of DNA damage and apoptosis of tumor cells (PMID: 23810788). Zejula (niraparib) is FDA-approved for use as maintenance therapy in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to first-line platinum-based chemotherapy, and as maintenance therapy in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer harboring deleterious or suspected deleterious germline BRCA mutations and in complete or partial response to platinum-based chemotherapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03431350||Phase Ib/II||Cetrelimab + Niraparib||A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer||Active, not recruiting||USA | ITA | GBR | ESP | CAN | BEL||1|
|NCT04592237||Phase II||Niraparib Cabazitaxel + Carboplatin + Cetrelimab Cetrelimab + Niraparib||Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer||Recruiting||USA||0|